Piper Sandler initiated coverage of Day One Biopharmaceuticals (DAWN) with an Overweight rating and $25 price target Piper thinks the stock move following the first two 2025 earnings reports is overdone and that these early decelerations of Ojemda are artifacts of a unique cancer indication wherein the prescribing physicians are risk-averse and slow to adopt novel therapies, the analyst tells investors in a research note. The firm continues to believe the clinical data will support strong penetration longer term.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One Biopharmaceuticals initiated with an Overweight at Piper Sandler
- Promising Growth and Stability Drive Buy Rating for Day One Biopharmaceuticals
- Day One Biopharma’s Earnings Call Highlights Growth and Strategy
- Promising Growth and Strategic Innovation Drive Buy Rating for Day One Biopharmaceuticals
- Buy Rating for Day One Biopharmaceuticals Amid Promising Future Catalysts Despite Current Challenges